McFadden David W, Calvario Elizabeth, Graves Cynthia
Department of Surgery, West Virginia University, Morgantown, West Virginia 26505, USA.
J Surg Res. 2007 Jun 1;140(1):1-5. doi: 10.1016/j.jss.2006.10.010.
Marketing costs exceed 30% of revenues for the pharmaceutical industry, with over 90% of the effort aimed at physicians. Although there are currently unprecedented numbers of regulatory activities focusing on relationships between the pharmaceutical industry and the medical profession, such legislation is often unrecognized or flouted. The potential influence, although minimized by both parties, must not be ignored. Physicians and drug companies will need to re-evaluate their responsibilities to their patients and their shareholders, and both groups should assume proactive and guidance roles in the transformation.
制药行业的营销成本超过了收入的30%，其中超过90%的精力都集中在医生身上。尽管目前有数量空前的监管活动聚焦于制药行业与医疗行业之间的关系，但此类法规常常未被重视或遭到无视。这种潜在影响尽管被双方都降至最低，但绝不能被忽视。医生和制药公司需要重新评估他们对患者和股东的责任，并且双方都应在变革中发挥积极主动的引导作用。
